SDGR — Schrodinger, Inc.

Is SDGR overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Health Information Services

Oversold As of November 17, 2026

Schrodinger, Inc. (SDGR) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Health Information Services) last closed at $27.36. The rating moved from Overbought to Oversold on November 14, 2026.

See all oversold Healthcare stocks →

AI analysis

Schrodinger combines a physics-based computational platform with growing software and services revenue opportunities that can meaningfully improve drug discovery efficiency. The company's long-term upside is supported by partnerships, licensing potential, and a large addressable market, while near-term performance will hinge on converting pilot programs into recurring deals, managing R&D spend, and maintaining cash runway. Market-wide risk-off sentiment and long pharma sales cycles are likely to keep the name volatile over the coming weeks, with upside tied to demonstrable commercial traction or material partner/license announcements.

Key factors

  • Proprietary physics-based computational platform that can shorten drug discovery timelines and attract pharma partnerships
  • Recurring and diversified revenue potential from software subscriptions, services, and milestone/licensing deals
  • Favorable sector dynamics around pharma M&A and partnerships that can create exit/licensing opportunities and validation events
  • Large total addressable market in discovery and materials modeling with secular demand for computational tools
  • Valuation that can look attractive relative to long-term growth potential in an otherwise cautious market environment

Risks

  • Execution risk: converting platform capability into consistent, large-scale, repeatable commercial revenue
  • Financial risk: history of R&D investment and potential for continued losses or cash runway pressure absent material licensing or equity raises
  • Competitive pressure from AI/ML-driven discovery companies and incumbent computational chemistry vendors
  • Revenue concentration and long sales cycles with pharma customers that can delay visibility and create volatility
  • Macroeconomic and risk-off market conditions that compress valuations for growth/biotech names and reduce M&A/takeout likelihood
  • Limited current public/social sentiment and lack of fresh EDGAR filing analysis in the provided data window reduces near-term information clarity

See today's live rating, score and targets

Members see the live hourly rating for SDGR — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.